PMV Pharmaceuticals, Inc. reported a corporate update and financial results for the first quarter of 2025, focusing on the ongoing Phase 2 PYNNACLE clinical trial evaluating rezatapopt, a treatment ...
PMV Pharma is laying off 30% of its staff as the precision oncology biotech prioritizes pushing its lead solid tumor candidate toward a phase 2 trial in the coming months. The drug, PC14586, became ...
PMV Pharmaceuticals (PMVP) develops small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's co-founder Dr. Arnold Levine was one of the four discoverers of the p53 protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results